Hyperparathyroidism and Peripheral Arterial Disease

Title:Hyperparathyroidism and Peripheral Arterial Disease

Volume: 22 Issue: 2

Author(s): Pier Luigi Antignani*, Mateja K Jezovnik, Ales Blinc, Dimitri P. Mikhailidis, Panagiotis Anagnostis, Gerit-Holger Schernthaner, Mojca Jensterle, Katica Bajuk Studen, Miso Sabovic and Pavel Poredos

Affiliation:

• Vascular Centre Nuova Villa Claudia, Rome, Italy

Keywords: Parathyroid hormone, chronic hypercalcaemia, vascular calcifications, peripheral arterial disease, parathyroidectomy, hyperparathyroidism.

Abstract:

Primary hyperparathyroidism (PHPT) is presented in various forms, including classic PHPT, characterised by increased parathyroid hormone (PTH) secretion, normohormonal PHPT, and normocalcaemic PHPT. Secondary hyperparathyroidism is characterised by increased PTH secretion triggered by factors such as vitamin D deficiency and kidney failure. This review aims to discuss the involvement of hyperparathyroidism (HPT) in atherosclerosis, including peripheral arterial disease (PAD).

The increased level of PTH is involved in developing subclinical and overt vascular diseases, encompassing endothelial dysfunction, vascular stiffness, hypertension, and coronary and peripheral arterial diseases. It has been consistently associated with an augmented risk of cardiovascular morbidity and mortality, independent of classical risk factors for atherosclerosis. Chronic hypercalcemia associated with increased levels of PTH contributes to the development of calcification of vessel walls and atherosclerotic plaques. Vascular calcification can occur in the intima or media of the arterial wall and is associated with stiffness of peripheral arteries, which the formation of atherosclerotic plaques and narrowing of the vessel lumen can follow. For treating hyperparathyroidism, particularly SHPT, calcimimetics, novel phosphorus binders and novel vitamin D receptor activators are used. However, they are ineffective in severe PHPT. Therefore, parathyroidectomy remains the primary therapeutic option of PHPT.

Cite this article as:

Antignani Luigi Pier*, Jezovnik K Mateja, Blinc Ales, Mikhailidis P. Dimitri, Anagnostis Panagiotis, Schernthaner Gerit-Holger, Jensterle Mojca, Studen Bajuk Katica, Sabovic Miso and Poredos Pavel, Hyperparathyroidism and Peripheral Arterial Disease, Current Vascular Pharmacology 2024; 22 (2) . https://dx.doi.org/10.2174/0115701611280905231227045826